AMRX

Amneal Pharmaceuticals, Inc. NASDAQ

Healthcare ·Drug Manufacturers - Specialty & Generic ·US · amneal.com

$13.11

Mkt Cap $4.2B

52w Low $7.02 72.5% of range 52w High $15.42

50d MA $12.88 200d MA $11.58

P/E (TTM) 55.8x

EV/EBITDA 10.6x

P/B 675.3x

Debt/Equity -38.6x

ROE -101.8%

P/FCF 14.6x

RSI (14) —

ATR (14) —

Beta 1.32

50d MA $12.88

200d MA $11.58

Avg Volume 2.0M

About

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmi…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	1M%	Guide ▲★
Apr 22, 2026	TNS	0.17	0.27	+58.8%	13.02	+1.9%	-1.5%	-2.8%	-3.8%	-3.5%	-2.2%	—	—
Feb 27, 2026	TNS	0.18	0.21	+16.7%	14.49	-1.8%	-4.7%	-5.0%	-8.1%	-8.2%	-8.5%	-17.5%	—
Oct 30, 2025	TNS	0.13	0.17	+30.8%	10.43	+1.8%	-4.1%	+3.7%	+7.4%	+8.8%	+12.1%	+18.0%	—
Aug 5, 2025	TNS	0.18	0.25	+38.9%	7.96	+4.1%	+2.1%	+1.1%	+3.1%	+7.3%	+11.1%	+20.0%	—
May 2, 2025	TNS	0.15	0.21	+40.0%	7.74	+0.6%	+3.0%	-2.6%	-7.2%	-6.7%	-3.6%	-4.1%	—
Feb 28, 2025	TNS	0.15	0.12	-20.0%	8.38	-5.0%	+3.5%	+4.5%	+5.5%	+7.0%	+4.5%	+0.0%	—
Nov 8, 2024	TNS	0.13	0.16	+23.1%	8.61	-5.3%	+1.4%	+6.9%	+7.4%	+4.9%	+4.5%	-6.0%	—
Aug 9, 2024	TNS	0.14	0.16	+14.3%	7.77	-1.3%	-1.5%	-3.0%	+1.2%	+0.5%	+1.8%	+8.9%	—
May 3, 2024	TNS	0.09	0.14	+55.6%	6.21	+0.6%	+8.9%	+7.1%	+4.8%	+6.1%	+4.2%	+6.4%	—
Mar 1, 2024	TNS	0.07	0.14	+100.0%	5.52	+10.9%	-0.9%	-2.2%	-3.3%	-3.8%	-3.8%	+9.6%	—
Nov 7, 2023	TNS	0.12	0.19	+58.3%	4.21	-0.7%	+2.4%	-3.6%	-1.4%	+0.2%	+1.7%	+11.4%	—
Aug 4, 2023	TNS	0.10	0.19	+90.0%	3.36	+7.1%	+22.3%	+36.6%	+33.3%	+25.9%	+25.9%	+13.7%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 2	Truist	Maintains	Buy → Buy	—	$13.81	$13.87	+0.4%	-0.3%	-3.6%	-3.7%	-4.0%	-4.1%
Oct 31	Piper Sandler	Maintains	Overweight → Overweight	—	$10.00	$10.18	+1.8%	+8.2%	+12.0%	+13.5%	+16.9%	+16.6%
Sep 16	JP Morgan	Maintains	Overweight → Overweight	—	$9.79	$9.83	+0.4%	-0.5%	-1.8%	+0.2%	+0.2%	+2.1%
Mar 3	Barclays	Maintains	Overweight → Overweight	—	$8.67	$8.69	+0.2%	+1.0%	+2.0%	+3.5%	+1.0%	+2.7%
Feb 24	JP Morgan	Upgrade	Neutral → Overweight	—	$7.83	$8.49	+8.4%	+6.0%	+8.6%	+7.7%	+7.0%	+10.7%
Nov 11	Piper Sandler	Maintains	Overweight → Overweight	—	$8.73	$8.79	+0.7%	+5.4%	+6.0%	+3.4%	+3.1%	-3.0%
Oct 2	Truist	Maintains	Buy → Buy	—	$8.70	$8.76	+0.7%	-1.3%	-1.7%	-0.6%	-2.8%	-0.5%
Sep 6	JP Morgan	Upgrade	Underweight → Neutral	—	$8.45	$8.56	+1.3%	-0.7%	+0.1%	-0.8%	-1.1%	+0.2%
Aug 13	Barclays	Maintains	Overweight → Overweight	—	$7.54	$7.47	-0.9%	+4.2%	+3.6%	+4.9%	+6.6%	+8.1%
Aug 12	Truist	Maintains	Buy → Buy	—	$7.65	$7.77	+1.6%	-1.4%	+2.7%	+2.1%	+3.4%	+5.1%
May 6	Truist	Maintains	Buy → Buy	—	$6.76	$6.82	+0.9%	-1.6%	-3.7%	-2.5%	-4.3%	-1.5%
May 6	Goldman Sachs	Maintains	Buy → Buy	—	$6.76	$6.82	+0.9%	-1.6%	-3.7%	-2.5%	-4.3%	-1.5%
Mar 21	Piper Sandler	Maintains	Overweight → Overweight	—	$6.08	$6.32	+3.9%	+3.5%	-0.2%	-2.8%	-3.8%	+0.7%
Mar 4	Goldman Sachs	Maintains	Buy → Buy	—	$5.47	$5.43	-0.7%	-1.3%	-2.4%	-2.9%	-2.9%	-1.5%
Jan 29	Barclays	Maintains	Overweight → Overweight	—	$5.49	$5.64	+2.7%	+4.9%	+0.4%	-2.6%	+0.4%	+0.5%
Nov 8	Truist	Maintains	Buy → Buy	—	$4.31	$4.38	+1.6%	-5.8%	-3.7%	-2.1%	-0.7%	+6.0%
Sep 6	Truist	Maintains	Buy → Buy	—	$3.82	$3.94	+3.1%	-3.1%	-3.1%	-1.3%	+0.5%	+4.7%
Aug 7	Piper Sandler	Maintains	Overweight → Overweight	—	$4.11	$4.27	+3.9%	+11.7%	+9.0%	+2.9%	+2.9%	-3.4%
Aug 7	Truist	Maintains	Buy → Buy	—	$4.11	$4.27	+3.9%	+11.7%	+9.0%	+2.9%	+2.9%	-3.4%
Aug 7	Barclays	Maintains	Overweight → Overweight	—	$4.11	$4.27	+3.9%	+11.7%	+9.0%	+2.9%	+2.9%	-3.4%
May 8	Piper Sandler	Maintains	Overweight → Overweight	—	$1.92	$2.00	+4.2%	+5.2%	-3.1%	-7.3%	-2.1%	+0.0%
Mar 29	Truist	Maintains	Buy → Buy	—	$1.27	$1.29	+1.6%	+3.1%	+7.1%	+9.4%	+14.2%	+7.1%
Mar 10	Barclays	Maintains	Overweight → Overweight	—	$1.67	$1.64	-1.8%	-8.4%	-12.0%	-14.4%	-18.6%	-19.2%
Mar 3	BMO Capital	Maintains	Market Perform → Market Perform	—	$1.99	$1.98	-0.5%	-3.5%	-8.5%	-11.6%	-15.6%	-16.1%
Mar 3	Goldman Sachs	Maintains	Buy → Buy	—	$1.99	$1.98	-0.5%	-3.5%	-8.5%	-11.6%	-15.6%	-16.1%
Aug 8	Goldman Sachs	Maintains	Buy → Buy	—	$3.18	$3.17	-0.3%	-1.6%	-2.8%	-1.3%	-8.2%	-0.6%
May 12	Goldman Sachs	Maintains	Buy → Buy	—	$3.26	$3.26	+0.0%	+4.3%	+5.8%	+5.2%	+13.5%	+6.7%
Mar 8	Goldman Sachs	Upgrade	Sell → Buy	—	$4.95	$5.15	+4.0%	+13.1%	+20.8%	+19.4%	+24.0%	+21.6%
Dec 14	Guggenheim	Upgrade	Neutral → Buy	—	$4.08	$4.37	+7.1%	+7.6%	+13.5%	+12.3%	+11.3%	+7.8%
Nov 9	SVB Leerink	Maintains	Market Perform → Market Perform	—	$4.13	$4.27	+3.4%	+1.5%	+1.5%	+0.7%	+0.0%	+0.2%
Oct 9	Piper Sandler	Maintains	Overweight → Overweight	—	$4.53	$4.60	+1.5%	+4.9%	+6.2%	+5.3%	+7.9%	+11.3%
Jul 27	Goldman Sachs	Maintains	Sell → Sell	—	$4.29	$4.25	-0.9%	-4.2%	-2.3%	+6.1%	+1.6%	+0.9%
May 13	SunTrust Robinson Humphrey	Maintains	Buy → Buy	—	$4.27	$4.31	+0.9%	+2.1%	-4.0%	-3.5%	+2.6%	+6.1%
May 12	SVB Leerink	Maintains	Market Perform → Market Perform	—	$4.56	$4.65	+2.0%	-6.4%	-4.4%	-10.1%	-9.6%	-3.9%
May 12	Guggenheim	Upgrade	Sell → Neutral	—	$4.56	$4.65	+2.0%	-6.4%	-4.4%	-10.1%	-9.6%	-3.9%
Apr 2	Morgan Stanley	Maintains	Equal Weight → Equal Weight	—	$3.03	$3.10	+2.3%	+0.7%	-5.3%	+3.6%	-4.0%	+2.3%
Feb 27	SunTrust Robinson Humphrey	Maintains	Buy → Buy	—	$3.85	$3.90	+1.3%	-1.6%	+0.0%	+3.4%	-0.8%	+6.2%
Jan 2	RBC Capital	Maintains	Sector Perform → Sector Perform	—	$4.82	$4.98	+3.3%	-1.0%	-2.1%	-1.9%	-2.9%	-6.2%
Dec 12	Raymond James	Downgrade	Outperform → Market Perform	—	$3.48	$4.69	+34.8%	+44.8%	+36.8%	+59.8%	+47.7%	+41.7%
Nov 12	JP Morgan	Downgrade	Neutral → Underweight	—	$2.65	$2.58	-2.6%	+1.9%	+3.8%	+2.3%	+3.8%	+6.8%
Nov 11	BMO Capital	Maintains	Market Perform → Market Perform	—	$2.73	$2.70	-1.1%	-2.9%	-1.1%	+0.7%	-0.7%	+0.7%
Nov 7	SVB Leerink	Downgrade	Outperform → Market Perform	—	$2.76	$2.71	-1.8%	-4.0%	-1.1%	-4.0%	-2.2%	-0.4%
Nov 7	Raymond James	Maintains	Outperform → Outperform	—	$2.76	$2.71	-1.8%	-4.0%	-1.1%	-4.0%	-2.2%	-0.4%
Sep 12	Guggenheim	Maintains	Sell → Sell	—	$3.46	$3.25	-6.1%	+0.9%	+0.9%	-3.5%	-8.4%	-5.8%
Aug 6	BMO Capital	Maintains	Market Perform → Market Perform	—	$3.02	$3.06	+1.3%	-1.0%	-3.6%	-1.0%	-3.6%	-6.0%
Jul 22	SVB Leerink	Upgrade	Market Perform → Outperform	—	$3.40	$3.60	+5.9%	+1.2%	+7.9%	+7.6%	+3.8%	+7.4%
Jul 11	RBC Capital	Downgrade	Outperform → Sector Perform	—	$4.36	$4.37	+0.2%	-7.1%	-15.1%	-19.5%	-25.0%	-22.0%
Jul 11	SunTrust Robinson Humphrey	Maintains	Buy → Buy	—	$4.36	$4.37	+0.2%	-7.1%	-15.1%	-19.5%	-25.0%	-22.0%
Jul 10	Raymond James	Downgrade	Strong Buy → Outperform	—	$6.81	$5.05	-25.8%	-36.0%	-40.5%	-45.7%	-48.5%	-52.0%
Jul 8	Piper Jaffray	Upgrade	Neutral → Overweight	—	$6.66	$7.28	+9.3%	+1.2%	+2.3%	-34.5%	-39.2%	-44.4%

Recent Filings

8-K

Amneal Pharmaceuticals, Inc. -- 8-K Filing

Amneal Pharmaceuticals acquired Kashiv product candidates with potential royalty payments to sellers of up to 25% of profits exceeding specified thresholds over twelve years.

Apr 22

8-K · 7.01 ! Medium

Amneal Pharmaceuticals, Inc. -- 8-K 7.01: Regulation FD Disclosure

Amneal Pharmaceuticals will host an earnings call today at 8:30 a.m. ET to discuss financial results, accessible via webcast on its investor relations website.

Feb 27

8-K · 1.01 !! High

Amneal Pharmaceuticals, Inc. -- 8-K 1.01: Material Agreement

Amneal Pharmaceuticals repriced its term loan credit agreement, likely reducing borrowing costs and improving financial flexibility for the pharmaceutical company.

Feb 3

Data updated apr 24, 2026 5:56pm · Source: massive.com